We also investigated the COL11A1 effect on the responsiveness of the cells to CDK4/6 inhibitors including palbociclib, abemaciclib and ribociclib, which are now frequently used in treating ER+ breast cancer patients27–29. Here, COL11A1 is linked to breast carcinoma.